key: cord-0988987-cekrqzw7
authors: de Michelena, P.; Torres, I.; Ramos-Garcia, A.; Gosalbes, V.; Ruiz, N.; Sanmartin, A.; Botija, P.; Puojois, S.; Huntley, D.; Albert, E.; Navarro, D.
title: Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant
date: 2022-02-02
journal: nan
DOI: 10.1101/2022.02.02.22270295
sha: 0b374087b8c4717138a5475fb96ef1c43d457a4c
doc_id: 988987
cord_uid: cekrqzw7

Objectives: It has been suggested that rapid antigen detection assays (RADT) may perform suboptimally in terms of sensitivity for the diagnosis of SARS-CoV-2 Omicron variant infection. To address this issue, we conducted a prospective study in primary health centers to evaluate the clinical performance of the Panbio COVID-19 Ag Rapid Test Device in nasopharyngeal specimens (NP) carried out at the point of care. Methods: We recruited 244 patients (median age, 40 years; range 2-96; 141 female) with clinical suspicion of COVID-19 (232 adults and 12 children). 228/244 patients had been fully vaccinated (two doses) with licensed COVID-19 vaccines prior to recruitment. Most patients (222/244) were SARS-CoV-2 naive prior to enrollment. Patients were tested by RT-PCR and RADT within 5 days since symptoms onset. Results: 126 patients (51.6%) tested positive by both RT-PCR and RADT, 90 patients (36.8%) returned negative results by both assays and 28 patients (11.4%) yielded discordant results (RT-PCR+/RADT-). No patients tested RT-PCR-/RADT+. Overall specificity and sensitivity of RADT was 100% (95% CI, 95.9-100%) and 81.8% (95% CI, 75-87.1%) respectively. The sensitivity of the assay increased from 79.6% (95% CI, 66.4-88.5) when considering specimens collected at days 0-1 after symptoms onset, to 86.4% (95% CI, 66.7-95.3) when grouping the specimens obtained on days 4-5. Conclusion: The Panbio COVID-19 Ag Rapid Test Device perform well (>=80% sensitivity) as a point-of-care test for early diagnosis of COVID-19 due to the Omicron variant in primary healthcare centers.

Keywords: SARS-CoV-2, Omicron variant, rapid antigen assay, COVID-19, field 46 performance study

A number of commercially available rapid antigen detection tests (RADT) targeting the 49 SARS-CoV-2 nucleocapsid protein (NP) have been shown to display a sensitivity of 50 over 80% compared to RT-PCR assays for diagnosis of SARS-CoV-2 infection in 51 symptomatic individuals, provided that testing is conducted within one week after 52 symptoms onset [1] . These RADT were optimized for detection of the ancestral Wuhan-53

Hu-1 variant, and the emergence of SARS-CoV-2 variants which incorporate non-54 synonymous mutations within the amino acid sequence of NP may impact on the 55 diagnostic efficiency of RADT. In this context, two studies [2, 3] showed that the 56 Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostic GmbH, Jena, Germany) 57 had decreased sensitivity for detection of SARS-CoV-2 Alpha (B.1.1.7) variant 58 compared to non-alpha lineages. As in many other countries, the SARS-CoV-2 Omicron 59 variant has overtaken the Delta variant and currently dominates in Spain 

We collected two NPs per patient, one of which (provided by the manufacturer) was 80 used for RADT while the other was placed in 3 mL of universal transport medium 81 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. As expected, median viral RNA load was significantly higher (P<0.0001) in RT-121 PCR+/RADT+ specimens than in those returning RT-PCR+/RADT-results (Fig. 1) . 122

The SARS-CoV-2 Omicron variant carries one or more mutations in the NP gene 124 Omicron and other variants of concern was not possible due to the absolute dominance 158 of the former at the time of study. Third, no cell cultures were performed for specimens 159 returning discordant RT-PCR/RADT results. Fourth, the small number of children, 160 SARS-CoV-2-experienced and unvaccinated individuals enrolled precluded conducting 161 robust subanalyses for these population groups. 162

In summary, we found the Panbio™ COVID-19 Ag Rapid Test Device to perform well 163 as a point-of-care test for early diagnosis of COVID-19 due to the Omicron variant in 164 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 2, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 2, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22270295 doi: medRxiv preprint

WA Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-189

CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants

Field 194 evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for

COVID-19 diagnosis in primary healthcare centres

Discordant SARS-CoV-2 PCR and